Summary
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
History
AnaptysBio was founded in 2005 by Brad Marsilio and Bobby Waugh. In 2012, the company received a Series A financing of $10 million. In 2015, they made their IPO, raising over $52 million. In 2017, they completed a phase 2a trial for the ANB020 drug and began the phase 2b trial.
Mission
AnaptysBio’s mission is to discover, develop, and commercialize novel antibody product candidates to treat inflammatory disorders, cancer, and other serious diseases.
Vision
AnaptysBio strives to become a leading player in the biotechnology industry by developing products that improve the quality of life of patients with serious illnesses.
Key Team
Mr. Dennis M. Mulroy (Chief Financial Officer)
Mr. Benjamin Stone (Sr. VP of Corp. Devel.)
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D. (Chief Medical Officer)
Ms. Beth Mueller (Sr. VP of HR)
Dr. Martin Dahl Ph.D. (Sr. VP of Research)
Recognition and Awards
AnaptysBio's ANB020 drug candidate was awarded the 'Pfizer Breakthroughs in Science Award' and 'Best Clinical Trial Award' in 2020.
References
United States 